SPL 9.20% 9.5¢ starpharma holdings limited

Astra Zeneca Quarterly, page-16

  1. 12,800 Posts.
    lightbulb Created with Sketch. 1391
    The Azd0466 AstraZeneca trial is expanding indications in phase 1 clinical trials globally as announced in February

    AstraZeneca’s significantly expanded clinical program for AZD0466 will include a multi-centre global Phase 1 study in acute leukaemias.

    This updated program will expedite development of AZD0466 with the objective of obtaining regulatory approval for specific indications of high unmet clinical need and this represents AstraZeneca's major focus.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
0.008(9.20%)
Mkt cap ! $39.14M
Open High Low Value Volume
9.0¢ 9.5¢ 8.8¢ $334.2K 3.710M

Buyers (Bids)

No. Vol. Price($)
2 50354 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
9.5¢ 22908 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.